#42

I really appreciate you all sharing this experiment on here. This is a question for all of you trying this, although it may be jumping ahead… but if you feel you have received benefits after the five weeks, do you envisage repeating this protocol on an annual or some other regular basis?

2 Likes
#43

I’m envisioning the possibility of yearly based on a quote from the patent application @Joseph shared.
“As another example, the present approach may be used on a recurring basis (e.g., yearly), to sustain the benefits and decrease the onset of aging side-effects.”

6 Likes
#44

Hi Joseph,

Thanks for raising awareness of this study. Good luck and I think everyone here is hoping you have good results. I’ve also obtained the antibiotics needed and will soon start.
There is one thing that I am uncertain about: the dose mentioned in the patent was, I believe, 100mg Doxycycline twice daily. But the dose needed to remain below antibiotic effects is, I believe, 20mg twice daily.
I thought that one of the good points about the proposed treatment was that it didn’t produce an antibiotic effect.
Is anyone able to reconcile this discrepancy for me?

2 Likes
#45

Same observations from me. The periodontal-related low dose of dox is 20 mg, under the brand name Periostat. But this DAV study uses anti-microbial strength 100 mg twice daily. That is the dosage used for lepstospirosis, a flood water borne bacterial disease in the tropics.

Even for malaria, it is 100 mg once a day for four weeks.

Prophylaxis: 2.2 mg/kg (up to adult dose of 100 mg) daily starting 1–2 days before travel, daily during travel, and daily for 4 weeks after leaving the malarious area.

Would 20 mg dox with azithromycin 250 mg twice weekly yield the same results? That is my personal question, for which I am doing a search. Azithromycin 250 every three days is indeed sub anti-microbial.

But since members here are already trying out the regimen, if it works, I would take the suggested dose.

5 Likes
#46

FWIW

The reference below are from a 9th November 2018 article. Titled;

“Michael Lisanti and antibiotics: the next cancer revolution”

His contact information is at the bottom of this posting.

Member “scta123” is the person who 9originally posted this article in another thread.

Review some of their other papers;

  1. C Scatena et al.: Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: A clinical pilot study. Frontiers in Oncology (2018)

  2. F Sotgia et al.: A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. Cell Cycle (2018)

  3. E M De Francesco et al.: Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochemical Journal (2018)

  4. U E Martinez-Outschoorn et al.: Cancer metabolism: a therapeutic perspective. Nature Reviews Clinical Oncology (2017)

  5. M Fiorillo et al.: Mitochondrial “power” drives tamoxifen resistance. Oncotarget (2017)

  6. M Peiris-Pagès et al.: Cancer stem cell metabolism. Breast Cancer Research (2016)

  7. R Lamb et al.: Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget (2015)

  8. U E Martinez-Outschoorn et al.: Caveolae and signalling in cancer. ­­Nature Reviews Cancer (2015)

Professor Michael P Lisanti, MD-PhD, FRSA
Chair in Translational Medicine
School of Environment & Life Sciences
University of Salford
+44 (0)1612 950 240
M.P.Lisanti@salford.ac.uk
www.salford.ac.uk/environment-life-sciences

2 Likes
#47

For my part, I’ve been trying for a week with 50 mg of doxycycline a day (half a 100 mg tablet), so that it’s just under the antibiotic dose + 250 mg of azythromycin every three days and 1000 mg of vitamin C. I’ve just finished my first week (52-year-old man, 181 cm, 68 kg).

7 Likes
#48

Looks like Michael Lisanti, MD and Federica Sotgia formulated a variation of doxycycline. They used that formulation, not generic doxycycline, at least for cancer.

Professor Michael Lisanti and Professor Federica Sotgia PhD, who both work in Translational Medicine at The University of Salford, have designed and tested new inhibitors of cancer metastasis that are based on an existing FDA-approved antibiotic, namely Doxycycline, first approved in 1967.

SLAS EU - Highlights from 2022 eBook Compilation of the top interviews, articles, and news in the last year.Download the latest edition

They have now chemically modified Doxycycline, making it 5 times more potent for the targeting of metastatic cancer cells. Fortunately, this modification also renders Doxycycline ineffective as an antibiotic, effectively removing the risk for the development of antibiotic resistant bacteria and infections.

So now I have to poke into the patent application. Did that N=1 77 year old man use the myristoyl amide doxycycline? Or was it generic doxycycline?

5 Likes
#49

Solved. When one accesses the patent application, and does a word search on his/her browser for “myristoyl”, you get quotes like the phrase below:

For example, myristoylation processes known in the art for the formation of myristoylated proteins can be used to form therapeutic agents according to this approach.

No wonder a patent was applied for. You cannot patent a generic, just by adding vit C. It is the myrsitoylated formulation that is patentable.

So now, it would be the results of Rmun above, that I will be waiting for.

Can one just add coconut oil (myristic acid source) to generic doxycycline and get the same results? Am not a chemist. I will search. But it would be a challenge for one without scientific training.

3 Likes
#50

Ask them?

Professor Michael P Lisanti, MD-PhD, FRSA
Chair in Translational Medicine
School of Environment & Life Sciences
University of Salford
+44 (0)1612 950 240

M.P.Lisanti@salford.ac.uk

[School of Science, Engineering and Environment]

(School of Science, Engineering and Environment)

1 Like
#51

You make an assumption.

The chemistry/bio-chemistry are clearly in the patent application.

1 Like
#52

Why? As you cited, it appears that doxycycline is prescribed as a prophylactic at a 100mg daily dose for at least 4 weeks plus vacation time.
So if you want the same results as the DAV protocol, why not just follow the protocol?

2 Likes
#53

The prophylactic dose is 100 mg daily for four weeks. The protocol is 100 mg twice daily for five weeks.

If the anti-microbial effect is sought to be avoided, it would appear that it is the other effects of dox which are being sought.

Abstract

translated from Japanese

本アプローチは、ミトコンドリア酸化ストレス誘導中に、正常細胞を阻害することなくミトコンドリア生合成を阻害することによって、老化細胞および加齢に関連する特徴を有する細胞を効果的に根絶する。複数の実施形態は、ミトコンドリア生合成を阻害し大ミトコンドリアリボソームを標的とする治療薬、ミトコンドリア生合成を阻害し小ミトコンドリアリボソームを標的とする治療薬、および酸化促進剤として挙動するまたはミトコンドリア酸化ストレスを誘導する治療薬を含み得る。いくつかの実施形態は、抗菌性を示さない抗生物質濃度を含み、それにより抗生物質耐性の懸念を最小とする。

This approach effectively eradicates aging cells and cells with age-related characteristics by inhibiting mitochondrial biosynthesis without inhibiting normal cells during mitochondrial oxidative stress induction. The embodiments include therapeutic agents that inhibit mitochondrial biosynthesis and target large mitochondrial ribosomes, therapeutic agents that inhibit mitochondrial biosynthesis and target small mitochondrial ribosomes, and act as pro-oxidants or mitochondrial oxidative stress. May include inducing therapeutic agents. Some embodiments include concentrations of antibiotics that do not exhibit antibacterial properties, thereby minimizing concerns about antibiotic resistance. seem that it is the other characteristics of doxycycline which are being employed.

I am not advocating for one or the other approach. These are mere ruminations. Anyway, we have both approaches being tested - the full protocol, and Rmun’s minimalist approach. So both ends of the spectrum are covered.

2 Likes
#54

You are aware their is an link posted to the US patent application, which is in English.

#55

I copied and pasted from that link, which is an application for a Japanese patent.

I did not expect the Japanese text. It came with the copied and pasted text.

#57

The article states that the modified Doxy is 5 times as potent as the unmodified one. So it could be that the original work used 100mg of Doxy, while the newer research used 20mg of Doxy-myristol?

1 Like
#58

Seems to be a reasonable inference.

#59

@Rmun, I’m considering joining you in trying this with a lower dose of doxycycline as well this time around. I’m 53 y/o and 5’1/100 pounds. I don’t know if size matters with this particular med. I have noticed in the past when I’ve actually been on doxycycline for an infection and taken it later in the day it disrupted my sleep. I’ve probably got about 10 days before my order arrives to decide.

3 Likes
#60

I’m also thinking of jumping on this bandwagon!

I’ve been interested in Doxycycline for some time, after taking a relatively potent course (100mg 2x/day 2-3 weeks, for an infection) which incidentally ~90% cleared up a long-standing, sometimes debilitating and worsening chemical allergy (perfumes especially) - that was a surprising and very welcome side-effect. That allergy has started to creep back this past year and I’ve been thinking about a reasonable protocol to restart this. This “DAV Therapy” might be a neat way to cover both interests in one.

6 Likes
#61

Yes- I am pausing Rapa. I will let you know what if any blood markers improve along with wellbeing.

1 Like
#62

Great podcast!

5 Likes
"Three-drug combination therapy for anti-aging"